Tata Memorial Hospital

Running trials

• Recruiting

  Glioma Adaptive Radiotherapy With Development of an Artificial Intelligence Workflow

  NCT06492486· Phase 2· Source

• Recruiting

  Study to Assess the Safety and Effectiveness of Novel Radiopharmaceutical Terbium-161 DOTATATE in Metastatic Neuroendocrine Tumors

  NCT07404176· Phase 2· Source

• Recruiting

  Asian Gynecological Brachytherapy Registry in Cervical Cancer

  NCT07196033· Source

• Recruiting

  Self-administered Remote Neurological Examination Using Mobile Application in Patients With Brain Tumors

  NCT07236840· Source

• Not yet recruiting

  Affordable Made-in-India Microspheres for Liver Cancer Therapy

  NCT07436988· Phase 1· Source

• Recruiting

  Systemic and Tumor Immune Response During Pelvic (Chemo)Radiation and/or Brachytherapy for Cervical Cancer

  NCT06804135· Source

• Recruiting

  A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue

  NCT06989437· Phase 2/3· Source

• Recruiting

  A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

  NCT07144280· Phase 3· Source

• Recruiting

  Intensity Modulated PrOton Therapy in Pediatric BRain Tumors (IMPORT)

  NCT07338526· Source

• Recruiting

  A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

  NCT07062965· Phase 3· Source

• Recruiting

  Study to Assess Adverse Events and Change in Disease Activity of Oral Venetoclax in Combination With Subcutaneous (SC) or Intravenous (IV) Azacitidine in Newly Diagnosed Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Standard Induction Therapy in India

  NCT07044687· Phase 4· Source

• Recruiting

  This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

  NCT06758401· Phase 3· Source

• Active, not recruiting

  A Study to Assess Safety of Teclistamab in Indian Participants With Relapsed and Refractory Multiple Myeloma

  NCT07030517· Phase 4· Source

• Recruiting

  Late Radiation Toxicities in Cervical and Endometrial Cancer: A Postoperative IMRT/Brachytherapy Study

  NCT07435623· Source

• Recruiting

  A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions

  NCT06499285· Phase 3· Source

• Recruiting

  Sentinel Node Biopsy Versus Limited Elective Neck Dissection in Early Cancers of Oral Cavity NoDe Negative

  NCT05774483· Source

• Recruiting

  Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)

  NCT06819007· Phase 3· Source

• Recruiting

  Reduced Length of ADT and ARTA With XRT in High-Risk Prostate Cancer (RELAX): A Randomised Trial

  NCT06818682· Phase 2· Source

• Recruiting

  Systemic Biomarkers to Predict Radiation-Induced Neurocognitive Decline

  NCT06779487· Source

• Recruiting

  Study Evaluating Safety Pharmacokinetics and Pharmacodynamics of AUR112 in Patients With Relapsed Advanced Lymphoma

  NCT06755450· Phase 1· Source

• Recruiting

  Tracing Brain Tumors Through Deep Time

  NCT06381531· Source

• Active, not recruiting

  Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease

  NCT06760637· Phase 3· Source

• Recruiting

  FAPi PET in Pancreatic Ductal Adenocarcinoma

  NCT07342231· Source

• Recruiting

  Craniospinal Irradiation in Histone AlteRed Midline Glioma

  NCT06720727· Source

• Recruiting

  A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy

  NCT06750094· Phase 3· Source

• Active, not recruiting

  Impact of Molecular Pathological And Clinical Features for Adjuvant Treatment Selection in Endometrial Cancer: Asian Registry

  NCT07354087· Source

• Recruiting

  Asian Watch-and-Wait Database (AWWD)

  NCT06631443· Source

• Recruiting

  A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

  NCT06662786· Phase 3· Source

• Recruiting

  A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

  NCT06561386· Phase 3· Source

• Recruiting

  First in Human Multicenter Open Name Dose-increase, Consolidation Method to Study Safety Drug-level in Blood & Drug Metabolism Clinical Activity of Oral JBI-778 in Lung Cancer Patients With, Without Brain Metastasis IDH Mutated WHO Grade 3,4 Recurrent Glioma, Salivary Glands Tumor

  NCT07755397· Phase 1· Source

• Recruiting

  Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer

  NCT06282575· Phase 3· Source

• Recruiting

  A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)

  NCT06345729· Phase 3· Source

• Recruiting

  Radiation Therapy in Unresectable Gall Bladder Cancer

  NCT06214572· Phase 2/3· Source

• Recruiting

  Efficacy and Safety of Tenalisib in Patients With Metastatic Triple Negative Breast Cancer (TNBC)

  NCT06189209· Phase 2· Source

• Recruiting

  Spatial and Temporal Characterization of Gliomas Using Radiomic Analysis

  NCT06036381· Source

• Active, not recruiting

  ARCHERY - Artificial Intelligence Based Radiotherapy Treatment Planning for Cervical, Head and Neck and Prostate Cancer

  NCT05653063· Source

• Recruiting

  A Study of Chlorophyllin for the Management of Brain Radio-necrosis in Patients With Diffuse Glioma

  NCT06016452· Phase 2· Source

• Recruiting

  Artificial Intelligence in CNS Radiation Oncology

  NCT06036394· Source

• Recruiting

  Cervical Cancer Oligo States (Recurrence, Metastasis) Multicentre Outcomes Study.

  NCT07400809· Source

• Recruiting

  Trastuzumab Plus Chemotherapy vs Chemotherapy Alone in First-line HER2 Positive Advanced Biliary Tract Cancer Patients

  NCT07062263· Phase 3· Source

• Active, not recruiting

  SCRT in TNT With or Without Chlorophyllin

  NCT05856305· Phase 2· Source

• Recruiting

  Postoperative Hypofractionated Radiation in Cervical and Endometrial Tumours: Phase II Study

  NCT05857631· Source

• Active, not recruiting

  A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)

  NCT05714202· Phase 3· Source

• Active, not recruiting

  A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer

  NCT05654623· Phase 3· Source

• Active, not recruiting

  Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)

  NCT05501886· Phase 3· Source

• Recruiting

  A Study to Learn More About How Safe Darolutamide is and How Well it Works Under Real World Conditions When Taken in Addition to Standard Androgen Deprivation Therapy (ADT) in Indian Participants With High-risk Non-metastatic Castration-resistant Prostate Cancer (nmCRPC)

  NCT05348876· Phase 4· Source

• Active, not recruiting

  A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy as First-Line Treatment in Subjects With Unresectable/Metastatic Melanoma

  NCT05732805· Phase 3· Source

• Active, not recruiting

  A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)

  NCT05296798· Phase 3· Source

• Active, not recruiting

  To Check Safety of Ayurvedic Oral Cannabis in Breast and Head and Neck Cancer

  NCT05969314· Phase 1· Source

• Recruiting

  Development of Clinically High Efficient Platforms for Individualised Treatment of Cervix Cancer

  NCT05102240· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Childhood cancers13 recruiting
• Lung cancer9 recruiting
• Cervical cancer8 recruiting
• Head and neck cancer5 recruiting
• Colorectal cancer4 recruiting
• Liver and biliary tract cancer4 recruiting
• Ovarian cancer3 recruiting
• Endometrial cancer2 recruiting
• Glioblastoma2 recruiting
• Hodgkin lymphoma2 recruiting
• Metastatic breast cancer2 recruiting
• Neuroendocrine tumours2 recruiting
• Pancreatic cancer2 recruiting
• Prostate cancer2 recruiting
• Acute myeloid leukemia1 recruiting
• Diffuse large B-cell lymphoma1 recruiting
• Gastric and esophageal cancer1 recruiting
• Myelodysplastic syndromes1 recruiting
• Sarcoma1 recruiting
• Triple-negative breast cancer1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Withdrawn

  Incidence of HIV Infection in Screening Indian Men Who Have Sex With Men

  NCT04142385· Source

• Withdrawn

  Incidence of HPV Infection and HPV-Associated Disease in Screening Indian Men Who Have Sex With HIV-Positive Men

  NCT04142398· Source

• Completed

  Brain Tumor Intraoperative Ultrasound Database

  NCT05062772· Source

• Completed

  Sentinel Node Biopsy in Early Oral Cancers a Tertiary Cancer Centre Experience

  NCT05950737· Source

• Completed

  India HIV-CervCa Project

  NCT07167069· Source

• Completed

  A Study to Evaluate the Safety and Efficacy of Polatuzumab Vedotin in Combination With Rituximab, Gemcitabine and Oxaliplatin Compared to Rituximab, Gemcitabine and Oxaliplatin Alone in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

  NCT04182204· Phase 3· Source

• Completed

  Study to Evaluate Safety Tolerability & Efficacy of Kyprolis (Carfilzomib) in Relapsed or Refractory Multiple Myeloma

  NCT03934684· Phase 4· Source

• Completed

  Adjuvant Radiotherapy in Early Stage Oral Cancers

  NCT03853655· Source

• Completed

  Regorafenib in Indian Patients With Metastatic Colorectal Cancer (mCRC).

  NCT03564938· Phase 4· Source

• Terminated

  A Study of Atezolizumab (Anti-PD-L1 Antibody) as Adjuvant Therapy After Definitive Local Therapy in Patients With High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck

  NCT03452137· Phase 3· Source

• Completed

  A Study to Evaluate the Safety and Efficacy of Lenvatinib in Participants With Refractory Differentiated Thyroid Cancer

  NCT03573960· Phase 4· Source

• Completed

  Radiosensitizing Effect of Nelfinavir in Locally Advanced Carcinoma of Cervix

  NCT03256916· Phase 3· Source

• Completed

  Image Based Brachytherapy in Locally Advanced Cervical Cancers - a Randomized Controlled Trial

  NCT03005743· Source

• Terminated

  Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment of Ph+ CML Resistant/Intolerant to ≥3 Prior CML Therapies

  NCT02629692· Phase 1/2· Source

Trial sites

• Tata Memorial Center5 trials
• Tata Memorial Centre15 trials
• Tata Memorial Centre - Tata Memorial Hospital1 trial
• Tata Memorial Hospital63 trials
• Tata Memorial Hospital; Dept of Medical Oncology1 trial
• Tata Memorial Hospital Mumbai1 trial
• Tata Memorial Hospital - Mumbai /ID# 2691771 trial
• Tata Memorial Hospital, Mumbai, India3 trials
• Tata Memorial Hospital, Nuclear Medicine & Molecular Imaging1 trial
• Tata Memorial Hospital, Parel1 trial
• Tata Memorial Hospital (Site 3205)1 trial
• Tata Memorial Hospital (TMH) Parel, and Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Kharghar1 trial
• Advanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Centre1 trial
• Advanced Centre of Treatment Research and Education In Cancer,Tata Memorial Centre1 trial
• Tata Memorial Hospital1 trial
• Tata Memorial Hospital1 trial

Conditions

Diseases this institution publishes on or runs trials for.

• Sarcoma40 works · 1 trials
• Cervical cancer37 works · 12 trials
• Childhood cancers29 works · 19 trials
• Head and neck cancer25 works · 10 trials
• Neuroendocrine tumours20 works · 3 trials
• Thyroid cancer14 works · 1 trials
• Acute lymphoblastic leukaemia13 works · 2 trials
• Hodgkin lymphoma12 works · 2 trials
• Chronic myeloid leukaemia8 works · 1 trials